COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

1362 Articles (1059 medRxiv, 303 bioRxiv)

Most recent first

Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis
Guo, C., Li, B., Ma, H., Wang, X., Cai, P., Yu, Q., Zhu, L., Jin, L., Jiang, C., Fang, J., Liu, Q., Zong, D., Zhang, W., Lu, Y., Li, K., Gao, X., Fu, B., Liu, L., Ma, X., Weng, J., Wei, H., Jin, T., Lin, J., Qu, K.
10.1101/2020.04.08.029769 — Posted: 2020-04-09
Decoding the lethal effect of SARS-CoV-2 (novel coronavirus) strains from global perspective: molecular pathogenesis and evolutionary divergence
Banerjee, S., Dhar, S., Bhattacharjee, S., Bhattacharjee, P.
10.1101/2020.04.06.027854 — Posted: 2020-04-09
Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue
Aguiar, J. A., Tremblay, B. J.-M., Mansfield, M. J., Woody, O., Lobb, B., Banerjee, A., Chandiramohan, A., Tiessen, N., Dvorkin-Gheva, A., Revill, S., Miller, M. S., Carlsten, C., Organ, L., Joseph, C., John, A., Jenkins, G., Mossman, K., Ask, K., Doxey, A. C., Hirota, J. A.
10.1101/2020.04.07.030742 — Posted: 2020-04-09
The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain
Chen, R., Yu, J., Wang, K., Chen, Z., Wen, C., Xu, Z.
10.1101/2020.04.07.030650 — Posted: 2020-04-09
3D Models of glycosylated SARS-CoV-2 spike protein suggest challenges and opportunities for vaccine development
Grant, O. C., Montgomery, D., Ito, K., Woods, R. J.
10.1101/2020.04.07.030445 — Posted: 2020-04-09
The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2
Chow, R. D., Chen, S.
10.1101/2020.04.07.030684 — Posted: 2020-04-09
Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19
Xing, J., Shankar, R., Drelich, A., Paithankar, S., Chekalin, E., Dexheimer, T., Rajasekaran, S., Tseng, C.-T. K., Chen, B.
10.1101/2020.04.07.030734 — Posted: 2020-04-09
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Corti, D., Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., Peter, A., Guarino, B., Spreafico, R., Cameroni, E., Case, J. B., Chen, R. E., Havenar-Daughton, C., Snell, G., Telenti, A., Virgin, H. W., Lanzavecchia, A., Diamond, M. S., Fink, K., Veesler, D.
10.1101/2020.04.07.023903 — Posted: 2020-04-09
The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro.
Bukreyeva, N., Mantlo, E. K., Sattler, R. A., Huang, C., Paessler, S., Zeldis, J.
10.1101/2020.04.07.028589 — Posted: 2020-04-09
Absence of SARS-CoV-2 infection in cats and dogs in close contact with a cluster of COVID-19 patients in a veterinary campus
Temmam, S., Barbarino, A., Maso, D., Behillil, S., Enouf, V., Huon, C., Jaraud, A., Chevallier, L., Backovic, M., Perot, P., Verwaerde, P., Tiret, L., van der Werf, S., Eloit, M.
10.1101/2020.04.07.029090 — Posted: 2020-04-09

RSS  Collection RSS | JSON

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).